ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TRB Trinity Biotech Plc

0.00
0.00 (0.00%)
- - Realtime Data
Share Name Share Symbol Market Type
Trinity Biotech Plc TG:TRB Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Rule 8-Tribal Group plc-Amend

01/07/2003 5:18pm

UK Regulatory


RNS Number:0316N
Merrill Lynch Investment ManagersLd
01 July 2003

                                 **AMENDMENT**

This announcement amends 8.1/8.3 RNS No.9367M released on 30th June, 2003 at 11:
27am. This is due to a purchase cancellation. All changes are indicated with an
                                  asterix (*).

     FORM 8.1/8.3

Lodge with Company Announcements Office (which will publicise and copy to the
Panel). Use separate form for each class of securities in which dealings have
been made.

     Date of disclosure: *1st July, 2003

DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKE-OVERS
AND MERGERS

Date of dealing: 27th June, 2003

Dealing in:           Tribal Group Plc          (Name of Company)

(1) Class of securities: 5p Ordinary Shares      (eg ordinary shares):

(2)
Amount bought                Amount sold                      Price per unit
                             44,283                           315p

(3)     Resultant total of the same class owned or controlled

     (and percentage of class *1,473,876     (2.80%)

(4)     Party making disclosure : MERRILL LYNCH INVESTMENT MANAGERS LIMITED



(5)     EITHER (a) Name of purchaser/vendor (note 1)

     OR (b) If dealing for discretionary client(s), name of fund management
organisation:

      MERRILL LYNCH INVESTMENT MANAGERS LIMITED



(6)     Reason for disclosure (Note 2)

     (a) associate of (i) offeror (Note 3)     XXX/NO

           (ii) offeree company     XXX/NO

     Specify which category or categories of associate (1-8 overleaf)


             If category (8), explain      ....................................
        ... .......................................




             (b) Rule 8.3 (ie disclosure because of ownership or control of 1%
        or more of

     the class of relevant securities dealt in)     YES/XX

Signed, for and on behalf of the party named in (4) above

(Also print name of signatory): Frances Morten

Telephone and extension number 020 7964 5952




        Note 1.     Specify owner, not nominee or vehicle company. If relevant,
        also identify controller of owner, eg where an owner normally acts on
        instructions of a controller.

        Note 2.     Disclosure might be made for more than one reason: if so,
        state all reasons.

        Note 3.     Specify which offeror if there is more than one.

        Note 4.     When an arrangement exists with any offeror, with the
        offeree company or with an associate of any offeror or of the offeree
        company in relation to relevant securities, details of such arrangement
        must be disclosed, as required by Note 6 on Rule 8.
        .......................................................................



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCEAKXFEEPDEFE

1 Year Trinity Biotech Chart

1 Year Trinity Biotech Chart

1 Month Trinity Biotech Chart

1 Month Trinity Biotech Chart

Your Recent History

Delayed Upgrade Clock